ATE476665T1 - Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion - Google Patents

Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion

Info

Publication number
ATE476665T1
ATE476665T1 AT06019669T AT06019669T ATE476665T1 AT E476665 T1 ATE476665 T1 AT E476665T1 AT 06019669 T AT06019669 T AT 06019669T AT 06019669 T AT06019669 T AT 06019669T AT E476665 T1 ATE476665 T1 AT E476665T1
Authority
AT
Austria
Prior art keywords
cardiac dysfunction
placenta
growth factor
related cardiac
level
Prior art date
Application number
AT06019669T
Other languages
English (en)
Inventor
Georg Hess
Andrea Horsch
Dietmar Zdunek
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE476665T1 publication Critical patent/ATE476665T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06019669T 2006-09-20 2006-09-20 Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion ATE476665T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06019669A EP1903339B1 (de) 2006-09-20 2006-09-20 Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion

Publications (1)

Publication Number Publication Date
ATE476665T1 true ATE476665T1 (de) 2010-08-15

Family

ID=37635722

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06019669T ATE476665T1 (de) 2006-09-20 2006-09-20 Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion

Country Status (8)

Country Link
US (1) US20090081702A1 (de)
EP (1) EP1903339B1 (de)
JP (1) JP4734306B2 (de)
CN (1) CN101196516A (de)
AT (1) ATE476665T1 (de)
CA (1) CA2601959A1 (de)
DE (1) DE602006015964D1 (de)
ES (1) ES2350255T3 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731910A1 (de) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten
EP1816477A1 (de) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG Verwendung von natriuretischen Peptiden und Plazentawachstumsfaktorwerten zur Risikostratifizierung von für Herzstresstests ausgewählten Personen
EP2496946B1 (de) 2009-11-03 2015-07-15 Roche Diagniostics GmbH NT-pro-ANP und sFlt-1 zur Differenzierung zwischen Kreislauf- und Ischämiereignissen
US20120219943A1 (en) * 2011-02-03 2012-08-30 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure
EP2490027A1 (de) * 2011-02-15 2012-08-22 Roche Diagnostics GmbH Mittel und Verfahren zur Diagnose von Schwangerschaftskomplikationen auf Grundlage von GDF-15 und PlGF/sFlt1
WO2013175314A2 (en) * 2012-05-23 2013-11-28 Convergent Engineering, Inc. System and method for detecting preeclampsia
CN107884570A (zh) * 2016-09-29 2018-04-06 韦彦余 一种孕妇先兆子痫检测试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3806694B2 (ja) * 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
AUPS169202A0 (en) * 2002-04-11 2002-05-16 Goetze, Jens Peter Neuropeptide assay
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
BRPI0312818B8 (pt) * 2002-07-19 2021-05-25 Beth Israel Deaconess Medical Ct Inc uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
DE50309809D1 (de) * 2002-11-16 2008-06-19 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
US20060257558A1 (en) * 2003-10-31 2006-11-16 Hiroshi Nomura Plasma polymerization of atomically modified surfaces
CA2511269A1 (en) * 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
DE602005001299T2 (de) * 2004-07-07 2008-02-07 Roche Diagnostics Gmbh Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
ATE519109T1 (de) * 2004-12-21 2011-08-15 Univ Yale Präeklampsie-diagnose
US20070111326A1 (en) * 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia

Also Published As

Publication number Publication date
EP1903339B1 (de) 2010-08-04
JP2008076394A (ja) 2008-04-03
JP4734306B2 (ja) 2011-07-27
CN101196516A (zh) 2008-06-11
ES2350255T3 (es) 2011-01-20
US20090081702A1 (en) 2009-03-26
DE602006015964D1 (de) 2010-09-16
CA2601959A1 (en) 2008-03-20
EP1903339A1 (de) 2008-03-26

Similar Documents

Publication Publication Date Title
Ahmad et al. Novel biomarkers in chronic heart failure
ATE469353T1 (de) Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen
CN101646945B (zh) 利用CT-proET-1与NT-proBNP的组合进行急性冠状动脉综合征的诊断和风险分层
ATE373827T1 (de) Kombination von markern für diabetes typ 1 und 2
RU2016134839A (ru) Биомаркер и способы для ранней диагностики болезни альцгеймера
US20140024053A1 (en) Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
RU2014118584A (ru) Композиции и способы лечения сердечной недостаточности
ATE452343T1 (de) Verbesserte vitamin-d-messung
CA2509063A1 (en) Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
JP2012507030A5 (de)
DE60025347D1 (de) Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
EP2287618A3 (de) Verfahren zur Diagnose neurodegenerativer Erkrankungen
DE60333471D1 (de) Polyklonaler-monoklonaler-elisa-assay zum nachweis von n-terminalem probnp
RU2019103403A (ru) Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
DE602005001299D1 (de) Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
RU2017114626A (ru) Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике
DE602006015964D1 (de) Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion
WO2009133197A3 (en) Levels of april in serum and use in diagnostic methods
FI3452829T3 (fi) Perm endometriumsyövän markkerina
ATE557277T1 (de) Verfahren zur diagnose von endometriose mittels tfpi-2 protein
RU2015116675A (ru) Способ прогнозирования риска возникновения рака или диагностирования рака у женщины
EP4107182A1 (de) Nachweisverfahren für zirkulierendes bmp10 (knochenmorphogenetisches protein 10)
WO2008125681A8 (en) Means and methods for assessing the risk of a cardiac intervention in patients suffering from a stable coronary heart disease based on gdf-15
JPWO2016143805A1 (ja) 膀胱がんの検出方法
EP4025915B1 (de) Test zur beurteilung von herzversagen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1903339

Country of ref document: EP